Valuation: NicOx SA

Market Cap 29.13M 33.4M 27.5M 24.97M 46.79M 3.21B 46.99M 329M 127M 1.63B 125M 123M 5.24B P/E 2026 *
-6.61x
P/E 2027 * 16.5x
Enterprise Value 29.13M 33.4M 27.5M 24.97M 46.79M 3.21B 46.99M 329M 127M 1.63B 125M 123M 5.24B EV / Sales 2026 *
9.71x
EV / Sales 2027 * 2.91x
Free-Float
99.65%
Yield 2026 *
-
Yield 2027 * -
Manager TitleAgeSince
Chief Executive Officer 55 27/02/2024
Director of Finance/CFO 58 31/12/2014
Corporate Officer/Principal - 31/12/2005
Director TitleAgeSince
Director/Board Member 55 07/04/2024
Chairman 64 15/07/2024
Director/Board Member - 15/07/2024
Change 5-day change 1-year change 3-year change Capi.($)
-7.95%-9.39% - - 33.44M
-0.51%+1.85%+79.80%+35.96% 363B
-1.22%-1.22%+20.85%-19.25% 65.62B
+2.14%+4.70%+46.37%+186.99% 12.45B
-0.29%+2.27%-5.37%-16.54% 7.6B
-1.89%-6.83%-27.65%-14.90% 4.49B
-2.06%-3.80%-34.68%+5.56% 4.19B
+1.48%+2.36%-31.20%-13.91% 2.92B
-2.27%+1.39%-8.48%+49.13% 2.49B
-0.41%-0.71%-28.25%-33.78% 1.93B
Average -1.32%+0.50%+1.27%+19.92% 51.64B
Weighted average by Cap. -0.60%+1.38%+65.50%+30.05%

Financials

2026 *2027 *
Net sales 3M 3.44M 2.83M 2.57M 4.82M 330M 4.84M 33.93M 13.09M 168M 12.92M 12.64M 540M 10M 11.47M 9.44M 8.57M 16.06M 1.1B 16.13M 113M 43.65M 559M 43.08M 42.12M 1.8B
Net income -5M -5.73M -4.72M -4.29M -8.03M -550M -8.07M -56.55M -21.82M -280M -21.54M -21.06M -900M 2M 2.29M 1.89M 1.71M 3.21M 220M 3.23M 22.62M 8.73M 112M 8.62M 8.42M 360M
Net Debt - -
Logo NicOx SA
Nicox SA is an international ophthalmology company developing innovative solutions to help maintain vision and improve ocular health. Nicox's lead program in clinical development is bimatoprost grenod (NCX 470), a novel nitric oxide-donating bimatoprost eye drop, for lowering intraocular pressure in patients with open-angle glaucoma or ocular hypertension. Nicox SA generates revenue from VYZULTA® in glaucoma, licensed exclusively worldwide to Bausch + Lomb, and ZERVIATE® in allergic conjunctivitis, licensed in multiple geographies, including to Harrow, Inc. in the United States, and Ocumension Therapeutics in the Chinese and in the majority of Southeast Asian markets.
Employees
-
LAST HOURS | 40% Discount: The Best Subscriber-Only Tools to Unlock Hidden Opportunities!
d
:
:
SEIZE THE OFFER!